Wan-Shon Lo

Shon’s matters for generic and branded pharma and biotech companies involve both large and small molecule products including Dupixent®, Repatha®, Praluent®, Sernivo®, Toviaz®, and Nuvigil®, among others. Shon particularly enjoys advising clients about the patent, regulatory, and antitrust issues that arise in the context of pharmaceutical product development and subsequent litigation.

Shon is a registered patent attorney and conducts patent and trademark opinion work, counseling, and prosecution. She also conducts due diligence supporting corporate transactions. Shon’s clients and technical proficiency span many industries and sectors, including biotech, pharmaceuticals, medical devices, high-tech, entertainment, food products, consumer products, and household fixtures.

Shon began conducting research as an undergraduate and continued as a research technician and graduate student in various laboratories in the fields of molecular, cellular, and developmental biology and neurobiology at MIT, Stanford and the University of Chicago. In the course of her prior career as a scientist, Shon co-authored several scientific articles, including an article published in Science magazine.

• A biosimilar manufacturer on patent issues
• An American multinational healthcare and medical products company on patent issues relating to product selection and development
• A market-leading orthopaedic device manufacturer in trade secret misappropriation and unfair competition-based investigations before the ITC
• The biopharmaceutical business of a leading German science and technology company in a license dispute
• Defendant in Promius Pharma LLC v. Perrigo et al. (E.D. Tex.) and Promius Pharma LLC v. Taro Pharmaceuticals Inc. (S.D.N.Y), a district court litigations concerning Sernivo®
• An academic medial hospital and physician-researcher in Immunomedics, Inc. v. Roger Williams Medical Center, et al. (D.N.J.),a district court litigation concerning patent infringement, antitrust, and state law claims relating to an experimental CAR-T cell therapy
• Plaintiff in Jesus Muhammad-Ali v. Final Call, Inc. (N.D. Ill.), a copyright infringement action involving unauthorized distribution of reproductions of plaintiff’s portraits
• Plaintiff in Immunex Corp. v. Sanofi et al. (C.D. Cal.), a district court litigation concerning Dupixent®
• Defendant in SwimWays Corp. & Kelsyus LLC v. Bestway (USA), Inc. (E.D. Va.), a district court litigation concerning pool floats
• Plaintiff in Elan Pharma Int’l Ltd. v. Actavis Labs. UT, Inc. (D. Del.), a district court litigation concerning Clindesse®
• Defendant in Pfizer, Inc. & UCB Pharma v. Alkem, Inc., et al. (D. Del.), a district court litigation concerning Toviaz®
• Defendant in In re Armodafinil (D. Del.), a district court litigation and also the appeal to the US Circuit Court of Appeals for the Federal Circuit concerning Nuvigil®
• Defendant in Leo Pharma A/S v. Tolmar, Inc. (D. Del.), the district court litigations concerning Dovonex® and Taclonex®
• Defendant in Galderma Labs, LP v. Tolmar, Inc. (N.D. Texas), a district court litigation concerning MetroGel®
• A national chain of photo studios in Picture Me Press v. CPI Corp. (N.D. Ohio), a trademark infringement litigation
• Defendant in Spoilage Cutter Co. v. World Kitchen (N.D. Ill.), a patent infringement and breach of contract litigation